Spero therapeutics announces presentation of spr719 (active moiety of spr720) in vitro data demonstrating low propensity for the development of resistance at idweek 2024

In vitro data on spr719 show low propensity for resistance development in ntm-pd mac strains when administered as a single agent and in combination with standard of care agents

SPRO Ratings Summary

SPRO Quant Ranking